Expanded Access to ANG1005 for Individual Patients
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from
 Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III
 Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with
 Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.
Inclusion Criteria:

 1. Neurologically stable

 2. Karnofsky performance status (KPS) ≥ 80

 3. Adequate laboratory results

 Exclusion Criteria:

 1. Radiotherapy within 3 months.

 2. Evidence of significant intracranial hemorrhage

 3. NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 Grade ≥ 2 neuropathy

 4. Inadequate bone marrow reserve

 5. Any evidence of severe or uncontrolled disease